Peter Aronstam - Jul 27, 2021 Form 4 Insider Report for Cytocom, Inc. (STAB)

Signature
/s/ Peter Aronstam
Stock symbol
STAB
Transactions as of
Jul 27, 2021
Transactions value $
$0
Form type
4
Date filed
7/29/2021, 09:33 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STAB Common Stock, par value $0.005 per share Award $0 +141K $0.00 141K Jul 27, 2021 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares received pursuant to an Agreement and Plan of Merger ("merger agreement"), entered into by Cytocom Inc. ("Old Cytocom") and Cleveland BioLabs, Inc ("New Cytocom" or "Issuer"). Per the "merger agreement", each share of Old Cytocom (i) common stock, (ii) preferred stock that was not converted into Old Cytocom common stock immediately prior to the effective time of the Merger, and (iii) each vested restricted stock unit of Old Cytocom (excluding, in each case, dissenting shares and shares held in treasury) converted into the right to receive a number of shares of New Cytocom common stock based on an exchange formula set forth in the merger agreement (which we refer to as the "merger consideration").